Oruka Therapeutics Interim Filing Shows Deepening Losses on Both Windows, Management Asserts Twelve-Month Liquidity Runway

Bottom line

- The company posted a wider net loss attributable to parent in the three-month reporting period than in the prior-year comparative, and the six-month year-to-date loss also widened relative to the prior-year comparative; both windows remained in a loss-to-loss position with no period of profitability appearing in this filing. - Operating loss followed the same pattern, with the three-month and six-month year-to-date operating losses both larger than the corresponding prior-year losses, again on a loss-to-loss basis.

- The reporting period is the company's interim filing identified by the cover-page form type and fiscal-period markers, filed under the listed CIK and accession number, and covering the three-month reporting period and the six-month year-to-date period as listed in the condensed consolidated statements of operations. - The source scope for the figures cited here is the unaudited condensed consolidated financial statements inside the filing, specifically the condensed consolidated statements of operations referenced through Item 1 of Part I and discussed in management's commentary under Item 2.

- Management describes the company as a clinical-stage biopharmaceutical issuer focused on monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, and frames its activity to date as substantially all resources devoted to advancing its development portfolio, organizing the company, and raising capital. - Management further states that existing cash, cash equivalents, and marketable securities are expected to fund operating plans for at least twelve months from the date the interim financial statements were issued, and that future financing is expected to come from a combination of equity offerings and debt financings until any product revenue is generated.

- Where the underlying drivers of the year-over-year loss changes are not attributed by the filing itself, no cause is asserted; for readers comparing clinical-stage biopharmaceutical interim windows, the Lineage Cell Therapeutics interim filing shows the opposite pattern of a quarter flipping to profit while the year-to-date window stays in loss, which provides useful contrast to this issuer's loss-to-loss trajectory in both windows.

- No peer or industry benchmark is presented in the filing itself, so any cross-company comparison rests on outside analysis rather than on the filing evidence. - The filing evidence does not attribute this change to any single cause.

Financial performance

- Reported results are unaudited and were prepared on the same basis as the annual statements, with only normal recurring adjustments applied; the interim periods presented are not necessarily indicative of full-year results. - Management confirms that existing cash, cash equivalents, and marketable securities are expected to fund operating plans for at least twelve months from the date the condensed consolidated financial statements were issued. - No significant changes to accounting policies or estimates were disclosed for the interim period, and no recently adopted accounting pronouncements were identified as material.

- A recently issued ASU on expense disaggregation was noted, with the Company currently evaluating its impact; the effective period falls outside the reporting horizon described. - Operating Income (Loss) for the three months ended June 30, 2026 was -$50,107,000, compared with -$28,429,000 for the three months ended June 30, 2025, a year-over-year decrease that remains a loss rather than a profit. - Operating Income (Loss) for the six months ended June 30, 2026 was -$86,541,000, compared with -$53,515,000 for the six months ended June 30, 2025, again a loss that deepened relative to the prior year-to-date window.

- Net Income (Loss) Attributable to Parent for the three months ended June 30, 2026 was -$41,206,000, versus -$24,574,000 for the three months ended June 30, 2025, with the authorized transition showing a loss-to-loss result that moved lower year over year. - Net Income (Loss) Attributable to Parent for the six months ended June 30, 2026 was -$73,026,000, versus -$45,573,000 for the six months ended June 30, 2025, continuing a loss-to-loss pattern that also decreased year over year. - The combined income-statement picture therefore shows losses that are larger than the prior-year equivalents on both the quarterly and year-to-date bases, with no offsetting profit line.

- Management characterizes the business as one that has devoted substantially all of its resources since inception to portfolio development, staffing, business planning, capital raising, and general and administrative support, and expects research and development and general and administrative costs to continue rising meaningfully. - The interim filing was reviewed against Item 1 for the condensed consolidated financial statements and Item 2 for management's discussion and analysis; Item 1A, Item 4, and the remainder of Part II were also walked through but did not surface new financial-performance drivers for this section.

- The cited note on significant accounting policies confirmed continuity with prior disclosures, and the cited note on use of estimates reiterated reliance on assumptions for research and development accruals and stock-based compensation valuation. - The cited note on the warrant obligation (Note 7) and the cited note on stockholders' equity (Note 10) are referenced for completeness but are not used to characterize period-over-period earnings movement here. - For the cash-flow comparison baselines relevant to operating performance, Net Cash Provided by (Used in) Operating Activities was lower year over year on the half-year basis, while Investing Activities shifted from positive in the prior period to negative in the current period and Financing Activities rose; Payments to Acquire Property, Plant, and Equipment were higher than the prior year-to-date period, and Accretion (Amortization) of Discounts and Premiums on Investments was lower than the prior year-to-date period.

- Year-over-year comparisons of operating and net loss figures were authorized at the loss-to-loss level, but the machine does not attribute the magnitude of change to any single cause. - The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison.

- A point of reference for a peer interim filing that similarly showed losses persisting with mixed direction is captured in Lizely Finance Earnings Analysis — Veru Inc. (VERU) Interim Filing: Losses Persist With Mixed Year-over-Year Direction, useful only as adjacent context and not as a benchmark for Oruka Therapeutics, Inc. under 10-Q for period-ended-2026-06-30.

Operating drivers and segments

- Oruka Therapeutics, Inc. reports as a single operating entity in this 10-Q filed for period-ended-2026-06-30 under accession 0001213900-26-087231, so segment-level revenue, cost-of-sales, or contribution-margin disclosures are not presented; the discussion here therefore rests on the consolidated operating result. - The Operating Income (Loss) line is the only margin-style anchor the catalog exposes for this section, and it is reported as a loss for both reporting windows. - For the three-month reporting period (the three months ended June 30, 2026), the Operating Income (Loss) was -$50,107,000 USD, versus a loss of -$28,429,000 USD in the prior-year comparative (the three months ended June 30, 2025); the authorized direction is a decrease (a deeper loss), with both periods in a loss-to-loss transition. - For the six-month year-to-date window (the six months ended June 30, 2026), the Operating Income (Loss) was -$86,541,000 USD, versus a loss of -$53,515,000 USD in the prior-year comparative (the six months ended June 30, 2025); the authorized direction here is also a decrease, again with a loss-to-loss transition. - Because segment evidence is absent, no segment-level commentary on operating drivers is possible from the filing evidence; readers should treat the consolidated operating loss as the single available margin proxy.

- Management's own framing, drawn from Item 1 (the financial statements narrative) and the related discussion in Item 2, describes Oruka Therapeutics, Inc. (Oruka Therapeutics, Inc.; ORKA) as a clinical-stage biopharmaceutical company focused on novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications. - Management states that, since inception, the company has devoted substantially all of its resources to advancing its portfolio of programs, organizing and staffing the company, business planning, raising capital, and providing general and administrative support for these operations. - Management further indicates that current and future programs will require significant research and development efforts, including preclinical and clinical trials, plus regulatory approvals to reach commercialization, and that, until any significant product revenue is generated, the company expects to finance operating activities through a combination of equity offerings and debt financings. - Management separately asserts that existing cash, cash equivalents, and marketable securities will be sufficient to fund the company's operating plans for at least twelve months from the date the condensed consolidated financial statements were issued; the supporting fair-value hierarchy references appear in Level 1, Level 2, and Level 3, with related disclosures in Note 7 and Note 10 for the warrant obligation and stockholders' equity.

- Independent analyst view: the consolidated operating loss is wider than the prior-year comparative in both windows on the authorized direction, which is consistent with management's stated profile as a clinical-stage issuer that has not yet generated product revenue and is spending on research and development. The filing evidence does not attribute this change to any single cause. The reader should note that management does not isolate a single driver for the larger loss; any attribution would need line-item detail that the filing evidence does not expose here. - Independent analyst view: the going-concern-style statement about a twelve-month operating runway is a management projection, not an audited outcome, and it depends on the fair-value hierarchy and stockholders'-equity disclosures referenced above; it should be read as a liquidity assertion rather than as evidence of segment-level profitability. - Independent analyst view: because the filing carries no segment breakdown, no peer or industry comparison is possible from this evidence; The filing evidence contains no peer or industry comparison. readers looking for a benchmarking anchor would need to consult external sources, such as the broader Lizely Finance earnings analyses covering other clinical-stage names, before drawing cross-issuer conclusions.

Cash flow and capital

- $268,470,000 USD was reported on the balance sheet as Cash and Cash Equivalents, at Carrying Value at the balance sheet date of June 30, 2026 as set out in Item 1. That figure represents the liquidity the company holds to fund operating needs, debt service, and capital allocation priorities as the period closes. - $7,950,000 USD was reported as Accounts Payable, Trade, Current at the balance sheet date of June 30, 2026 in Item 1, reflecting the short-term obligations due to operating vendors and counterparties.

Read together with the cash balance above, it provides a snapshot of working-capital positioning at the reporting date. - Cash use during the six months ended June 30, 2026 continued to be dominated by operating outflows. Net Cash Provided by (Used in) Operating Activities was -$56,723,000 USD over the six-month year-to-date window.

The prior-year comparative for the six-month year-to-date window, the six months ended June 30, 2025, recorded Net Cash Provided by (Used in) Operating Activities of -$44,014,000 USD. The authorized year-over-year direction for this line is a decrease, and the transition remains within a loss-to-loss pattern; the deeper reported figure simply describes a larger cash burn in the current window rather than a change in the nature of the activity. The filing evidence does not attribute this change to any single cause.

- Investing activity shifted to a net outflow during the six months ended June 30, 2026. Net Cash Provided by (Used in) Investing Activities was -$425,384,000 USD in the current six-month year-to-date window. The prior-year comparative window, the six months ended June 30, 2025, recorded Net Cash Provided by (Used in) Investing Activities of $47,726,000 USD.

The authorized year-over-year direction for this line is a decrease, consistent with the shift from a positive prior-year figure to a negative current figure. - Investing detail is anchored in the property, plant, and equipment line. Payments to Acquire Property, Plant, and Equipment were $73,000 USD over the six months ended June 30, 2026 and $47,000 USD over the six months ended June 30, 2025.

The authorized year-over-year direction for capital expenditures is an increase, indicating that property, plant, and equipment investment rose relative to the prior-year six-month year-to-date window even as the broader investing line moved to a use of cash. The filing evidence does not attribute this change to any single cause. - Financing activity was a source of cash in both windows.

Net Cash Provided by (Used in) Financing Activities was $703,642,000 USD for the six months ended June 30, 2026 and $109,000 USD for the six months ended June 30, 2025. The authorized year-over-year direction is an increase, consistent with continued external capital formation during the current six-month year-to-date window. - Capital-allocation context from Item 1 discusses preferred-stock mechanics, pre-funded warrant activity, the Paruka Warrant Obligation covered in Note 7, and Series B preferred stock detailed in Note 10.

Management commentary in Item 2 also describes the April underwritten public offering and the ATM program with TD Securities (USA) LLC referenced in Item 1, noting that no shares were issued under the ATM program during the three months ended within the current window. The filing evidence does not attribute this change to any single cause. - Read together, the statements show liquidity sourced through financing, applied to a larger operating cash burn and a higher level of property, plant, and equipment investment, with a working-capital position reflected by the cash and accounts payable balances above.

The filing evidence contains no peer or industry comparison.

Peer and historical context

On a year-over-year basis, the headline profitability lines for Oruka Therapeutics, Inc. (ORKA) continued to print losses in both windows reported in this 10-Q for period-ended-2026-06-30 (accession 0001213900-26-087231). The operating result remained negative on the three-month window against the prior-year quarter, and on the six-month year-to-date window against the prior-year comparative, with no transition into profit on either horizon. The bottom line mirrored the operating line: net loss attributable to parent was wider than the prior-year quarter and wider than the prior-year half-year. The authorized year-over-year directions on operating income and net income are both "decrease" with a "loss to loss" transition, so the directional read is consistent across both the quarter-over-quarter and the half-year-over-half-year views. Because every line in the matrix remains a loss, the year-over-year movement is best read as a deepening of the loss rather than a shift from profitability to loss.

Cash consumption followed the same directional pattern on the operating-cash-flow line, where the authorized direction is "decrease" and both the current six-month window and the prior-year comparative print negative cash flow. Two other authorized year-over-year movements sit alongside this: financing activities shifted upward while investing activities shifted downward on a cash basis, and capital expenditure payments increased versus the prior-year comparative. Discount accretion on investments decreased on a year-over-year basis. Together these read as a higher outflow profile on operations, a larger investment outflow, and a larger financing inflow, consistent with continued funding of operations by external sources rather than a self-funding trajectory.

The filing itself does not bundle any peer or industry benchmark, so there is nothing in the cited note set, Item 1 financial statements, Item 2 MD&A, Item 4 controls, or the stockholder-equity disclosure in Note 10 to anchor a like-for-like comparison against other clinical-stage issuers for the same period. For that dimension, the only honest read is that the filing evidence contains no peer or industry comparison, which limits any cross-issuer inference to directional commentary on this single filing.

A reader looking to contrast this trajectory with a clinical-stage peer that did flip to a profit on the quarterly window can review Lineage Cell Therapeutics Interim Filing: Quarterly Net Result Flips to Profit While Year-to-Date Window Stays in Loss for a same-side but opposite-quarter outcome, and a reader looking for a wider revenue-and-profit comparator in an unrelated sector can pair this read with REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing to bracket the directional range across the period.

The directional and causal split is therefore clean: every authorized line moved in the direction flagged in the catalog, no line printed a profit, and no single driver is named in the evidence for the wider operating and net loss. The filing evidence does not attribute this change to any single cause.

Scenario analysis

- The base scenario reflects a continuing clinical-stage loss profile, with the three-month and six-month net result both reported as losses attributable to parent on the face of the consolidated statements of operations in Item 1. - Compared with the prior-year three-month and six-month comparative windows, the authorized direction for net income attributable to parent is a decrease, and the transition stays in loss across both windows, indicating that the underlying earnings trajectory has not yet inflected and the base expectation is another period of losses in line with the cited comparator. - The base scenario is supported only by the authorized direction and transition labels above; the filing evidence does not quantify the size of the loss, nor does it provide a causal attribution. Where a cause would normally be narrated, the section instead records The filing evidence does not attribute this change to any single cause..

- The upside case contemplates a narrower loss than the prior-year comparators, with net income attributable to parent still in loss across both the three-month and six-month windows per the authorized direction labels, but moving toward break-even rather than widening. - Supporting evidence is limited to the four net income facts disclosed in Item 1 for the three months ended June 30, 2026, the three months ended June 30, 2025, the six months ended June 30, 2026, and the six months ended June 30, 2025, alongside the authorized direction labels that frame the comparative envelope. - Operational or financing tailwinds referenced in the cited note include the outstanding Paruka warrants disclosed in Note 7, the Series B convertible preferred stock terms described in Note 10, and the at-the-market program mentioned in the equity narrative, any of which could in principle broaden the funding runway if exercised. The filing evidence does not estimate how these instruments would translate into a narrower loss, so the upside remains a directional construct only, with The filing evidence does not attribute this change to any single cause. recorded where a driver would normally be named. - Readers tracking parallel interim filings can cross-reference the Lineage Cell Therapeutics interim filing to see how a narrow-loss-to-profit inflection has been framed elsewhere, though the filing here does not assert such an inflection.

- The downside case envisions a wider loss than the prior-year comparators, consistent with the authorized direction for net income attributable to parent being a decrease in both the three-month and six-month windows and the transition remaining in loss. - The downside is supported by the same four net income facts drawn from Item 1; the fair-value hierarchy disclosures in Level 1, Level 2, and Level 3 point to a cash and equivalents concentration that is sensitive to market pricing, which is the only stress channel the filing evidence explicitly flags. - The cited note on the Paruka Warrant Obligation in Note 7 and the Series B terms in Note 10 are also visible pressure points because both could dilute existing holders or alter the capital structure if triggered, but the filing evidence does not quantify the impact, so The filing evidence does not attribute this change to any single cause. is recorded for any gap narration. - Comparable interim coverage that frames persisting losses with mixed year-over-year direction is available in the Lizely Finance Earnings Analysis on Veru Inc., useful as a structural analogue rather than a direct comparison.

Risks and what to watch

The headline risk embedded in this 10-Q from Oruka Therapeutics, Inc. for period-ended-2026-06-30 is that both reported windows remain loss-making, and on the authorized direction both losses deepened versus the prior comparatives. Net Income (Loss) Attributable to Parent for the three-month reporting period the three months ended June 30, 2026 was -$41,206,000 USD, compared with -$24,574,000 USD for the three months ended June 30, 2025. Net Income (Loss) Attributable to Parent for the six-month year-to-date period the six months ended June 30, 2026 was -$73,026,000 USD, versus -$45,573,000 USD for the six months ended June 30, 2025. Both comparisons are authorized as transitions that stay in loss territory, with the authorized direction flagged as a decrease on both the quarterly and the half-year bases — that is, the loss widened rather than narrowed on a year-over-year basis.

Reported facts - The filing reports a wider parent-attributable net loss on both the quarter and the six-month year-to-date basis than in the prior-year comparatives, with the authorized direction flagged as a decrease. - Operating Income (Loss) followed the same pattern on both reported windows, registering as a loss in both the current and the prior-year periods (per the authorized direction, a decrease) and remaining in loss territory throughout.

Management explanations - The narrative surrounding these figures ties to share-based compensation and equity-plan activity disclosed in the cited note, but the filing does not draw a direct line from those grants to the bottom-line movement.

Analyst inference - Because both Net Income (Loss) Attributable to Parent and Operating Income (Loss) sit deeper in loss territory on a year-over-year basis on the authorized direction, the headline takeaway is that the operating profile remains negative on both observed windows — a useful framing for risk discussions, not a forecast.

Counter-evidence - Financing Activities on the half-year window moved higher on a year-over-year basis (per the authorized direction), which softens the cash-runway read by showing fresh external financing during the period. - Investing Activities on the half-year window shifted from a positive cash inflow in the prior-year comparative to a cash outflow in the current period (per the authorized direction, a decrease from a positive base), suggesting that liquidity this half-year is being financed rather than generated by either operations or investment activity. - Property, plant, and equipment spend on the half-year window was higher than the prior-year comparative (per the authorized direction), which can be read alongside the investing shift as a deployment signal.

Unknowns - The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison. - The filing evidence does not disclose segment-level detail for this dimension.

Metrics to watch next period - Whether the Net Income (Loss) Attributable to Parent for the three-month window narrows relative to the current quarter's loss figure, signaling any inflection in operating economics. - Whether Operating Income (Loss) on the half-year window begins to compress the loss after consecutive periods of deterioration. - Whether the Financing Activities increase on the half-year window continues or reverses, which would change the read on runway management. - Whether the Investing Activities flip from positive to negative reverses in subsequent filings, which would shift the read on how cash is being deployed.

Readers comparing patterns can contrast the persistent-loss shape here against the Lineage Cell Therapeutics Interim Filing where one window flipped to profit — a useful reminder that the same headline label can mask very different operating stories.